Multiple sclerosis onset during etanercept treatment.
Gomez-Gallego
Maria
M
Meca-Lallana
Jose
J
Fernandez-Barreiro
Andres
A
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008279:Magnetic Resonance Imaging / Q000379:methods; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D011239:Prednisolone / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000134:cerebrospinal fluid
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D008776:Methylprednisolone Hemisuccinate; D011239:Prednisolone; D000068800:Etanercept